Jiangsu Hengrui Pharmaceuticals (01276): Rivaroxaban tablets approved to conduct clinical trials.

Jiangsu Hengrui Pharmaceuticals (01276) announces that recently, the company has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for Rularem tablets. Clinical trials will be conducted soon. Rularem tablets are second-generation AR inhibitors, which have stronger AR inhibitory effects compared to first-generation AR inhibitors, and have no stimulating effects. The company's Rularem tablets have been approved for market in 2022 for the treatment of patients with metastatic hormone-sensitive prostate cancer with high tumor burden (mHSPC). Currently, there are several second-generation AR inhibitors on the market domestically and internationally, such as enzalutamide, apalutamide, and darolutamide. According to data from the EvaluatePharma database, the global sales of similar products to Rularem tablets are estimated to be approximately $11.037 billion in 2024. As of now, the cumulative research and development investment in the Rularem tablet project is about $693 million.